Literature DB >> 19787813

Hepatitis C drug development at a crossroads.

David R Nelson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787813     DOI: 10.1002/hep.23208

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  Identification of hepatoprotective flavonolignans from silymarin.

Authors:  Stephen J Polyak; Chihiro Morishima; Volker Lohmann; Sampa Pal; David Y W Lee; Yanze Liu; Tyler N Graf; Nicholas H Oberlies
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Optimized high-throughput screen for hepatitis C virus translation inhibitors.

Authors:  Katherine E Berry; Betty Peng; David Koditek; Douglas Beeman; Nikos Pagratis; Jason K Perry; Jay Parrish; Weidong Zhong; Jennifer A Doudna; I-hung Shih
Journal:  J Biomol Screen       Date:  2011-02

Review 3.  Targeting viral infection by microRNA inhibition.

Authors:  Ashley P E Roberts; Catherine L Jopling
Journal:  Genome Biol       Date:  2010-01-26       Impact factor: 13.583

4.  Targeting microRNA-122 to Treat Hepatitis C Virus Infection.

Authors:  Catherine L Jopling
Journal:  Viruses       Date:  2010-07-05       Impact factor: 5.818

5.  Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis.

Authors:  Mehnaaz Sultan Khuroo; Naira Sultan Khuroo; Mohammad Sultan Khuroo
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.

Authors:  Teresa L Kauf; Ateesha F Mohamed; A Brett Hauber; Derek Fetzer; Atiya Ahmad
Journal:  Patient       Date:  2012       Impact factor: 3.883

7.  Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates.

Authors:  Hany R Alwakeel; Hasan E Zaghla; Nabeel A Omar; Hasan A Alashinnawy; Eman A Rewisha; Laura E Matarese; Azza A Taha; Hossam M Kandil
Journal:  Int J Med Sci       Date:  2013-10-31       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.